{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:34:26Z","timestamp":1780587266813,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005196","name":"Bureau of Justice Assistance","doi-asserted-by":"publisher","award":["2011-D6-BX-K052"],"award-info":[{"award-number":["2011-D6-BX-K052"]}],"id":[{"id":"10.13039\/100005196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.drugalcdep.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T12:23:09Z","timestamp":1553257389000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"special_numbering":"C","title":["Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-8964","authenticated-orcid":false,"given":"Gail K.","family":"Strickler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.B.","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant T.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Kreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0005","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0010","series-title":"Mandatory PDMP Use","author":"Brandeis University Prescription Drug Monitoring Program (PDMP) Training and Technical Assistance Center (TTAC)","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0015","first-page":"77","article-title":"The effect of prescription drug monitoring programs on opioid utilization in Medicare","volume":"10","author":"Buchmueller","year":"2018","journal-title":"Am. Econ. J. Appl. Econ."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0020","series-title":"Prevention Status Reports, National Summary: Prescription Drug Overdose","author":"Centers for Disease Control and Prevention (CDC)","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J. Pain"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2015.02.010","article-title":"Abrupt decline in oxycodone-caused mortality after implementation of Florida\u2019s prescription drug monitoring program","volume":"150","author":"Delcher","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0035","series-title":"VA\/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. The Management of Opioid Therapy for Chronic Pain Working Group","author":"Department of Veterans Affairs (VA) and The Department of Defense (DoD)","year":"2010"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0040","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0045","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1377\/hlthaff.2016.0448","article-title":"Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates","volume":"35","author":"Dowell","year":"2016","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review","volume":"168","author":"Fink","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0055","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006-2015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0060","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1377\/hlthaff.2017.1321","article-title":"Four states with robust prescription drug monitoring programs reduced opioid dosages","volume":"37","author":"Haffajee","year":"2018","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0065","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999\u20132016","volume":"294","author":"Hedegaard","year":"2017","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0070","series-title":"Lessons Learned from Mandating Prescriber Compliance","author":"Hopkins","year":"2014"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0075","series-title":"Bureau of Justice Assistance Prescription Drug Monitoring Program Performance Measures Report: January 2009 Through June 2012. Brandeis University Prescription Drug Monitoring Program Center of Excellence","author":"Kreiner","year":"2013"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.addbeh.2017.08.032","article-title":"Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain","volume":"76","author":"Lin","year":"2018","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0085","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1536867X1501500208","article-title":"Conducting interrupted time-series analysis for single- and multiple- group comparisons","volume":"15","author":"Linden","year":"2015","journal-title":"Stata J."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0090","first-page":"648","article-title":"Potential misuse and inappropriate prescription practices involving opioid analgesics","volume":"19","author":"Liu","year":"2013","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0095","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/add.13741","article-title":"Do more robust prescription drug monitoring programs reduce prescription opioid overdose?","volume":"112","author":"Pardo","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0100","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1377\/hlthaff.2015.1496","article-title":"Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates","volume":"35","author":"Patrick","year":"2016","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1526-4637.2011.01260.x","article-title":"A history of being prescribed controlled substances and risk of drug overdose death","volume":"13","author":"Paulozzi","year":"2012","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6409a1","article-title":"Controlled substance prescribing patterns\u2014Prescription Behavior Surveillance System, eight states, 2013","volume":"64","author":"Paulozzi","year":"2015","journal-title":"MMWR Surveill. Summ."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2017.12.002","article-title":"Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings","volume":"184","author":"Pauly","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0120","series-title":"Prescription Drug Monitoring Programs: Evidence-Based Practices to Optimize Prescriber Use. A Report Prepared by the Pew Charitable Trusts and the Institute for Behavioral Health","author":"Pew Charitable Trusts","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0125","first-page":"849","article-title":"Increases in heroin overdose deaths \u2013 28 states, 2010\u20132012","volume":"63","author":"Rudd","year":"2014","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0130","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/ajt.14905","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants\u2014United States, 2015\u20132016","volume":"18","author":"Seth","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0135","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.5888\/pcd12.150187","article-title":"How do you know which health care effectiveness research you can trust? A guide to study design for the perplexed","volume":"12","author":"Soumerai","year":"2015","journal-title":"Prev. Chronic Dis."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0140","series-title":"2016 Ohio Automated Rx Reporting System (OARRS) Annual Report","author":"State of Ohio Board of Pharmacy","year":"2017"},{"issue":"12","key":"10.1016\/j.drugalcdep.2019.02.010_bib0145","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamasurg.2018.2666","article-title":"Association of the use of a mandatory prescription drug monitoring program with prescribing practices for patients undergoing elective surgery","volume":"153","author":"Stucke","year":"2018","journal-title":"JAMA Surg."},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0150","series-title":"Practitioner Requirements for Accessing the West Virginia Controlled Substances Monitoring Program Database, in Title Number 11 West Virginia Code \u00a7 60A.9-Sa(b)","author":"West Virginia Board of Medicine","year":"2012"},{"key":"10.1016\/j.drugalcdep.2019.02.010_bib0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.drugalcdep.2018.03.036","article-title":"Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing","volume":"188","author":"Winstanley","year":"2018","journal-title":"Drug Alcohol Depend."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161930081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161930081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:56:06Z","timestamp":1759827366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037687161930081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":31,"alternative-id":["S037687161930081X"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.010","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}